Epcoritamab and reduced chemo for older or frail lymphoma patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma (DLBCL or similar) that hasn't been treated before.
- You must be at least 70 years old (or 80+, or 70–79 and not able to have strong chemo).
- You need to have at least one tumor that can be measured on a scan (larger than about 1.5 cm for a lymph node, or 1 cm elsewhere).
- You must have good organ function, like kidneys and heart (ejection fraction at least 45%).
- You must not have had prior chemotherapy or immunotherapy for this lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
This trial tests a lower-dose combination of chemotherapy drugs (R-mini-MCOP) for people aged 80 or older who have just been diagnosed with a common type of lymphoma called DLBCL. The goal is to see if this gentler approach is effective and easier to tolerate.
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.